Vasoactive intestinal peptide (VIP) induces c-fos expression in LNCaP prostate cancer cells through a mechanism that involves Ca2+ signalling. Implications in angiogenesis and neuroendocrine differentiation.

Collado, Beatriz

Vasoactive intestinal peptide (VIP) induces c-fos expression in LNCaP prostate cancer cells through a mechanism that involves Ca2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. [electronic resource] - Biochimica et biophysica acta Jun 2005 - 224-33 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0006-3002

10.1016/j.bbamcr.2005.04.009 doi


Calcium--metabolism
Calcium Signaling--drug effects
Cell Differentiation--drug effects
Cell Line, Tumor
Chelating Agents--pharmacology
Cyclic AMP--metabolism
Drug Interactions
Egtazic Acid--analogs & derivatives
Gene Expression Regulation--drug effects
Humans
Isoquinolines--pharmacology
Male
Neuropeptides--metabolism
Prostatic Neoplasms
Proto-Oncogene Proteins c-fos--drug effects
RNA, Messenger--drug effects
Sulfonamides--pharmacology
Vascular Endothelial Growth Factor A--metabolism
Vasoactive Intestinal Peptide--pharmacology